Open AccessSurvival Benefit of Neoadjuvant Chemotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction
Author(s) -
Satoshi Suzuki,
Shingo Kanaji,
Naoki Urakawa,
Gosuke Takiguchi,
Hiroshi Hasegawa,
Yoshiko Matsuda,
Kimihiro Yamashita,
Takeru Matsuda,
Taro Oshikiri,
Tetsu Nakamura,
Yoshihiro Kakeji
Publication year - 2021
Publication title -
cancer diagnosis and prognosis
Language(s) - English
Resource type - Journals
ISSN - 2732-7787
DOI - 10.21873/cdp.10025
Subject(s) - oxaliplatin , medicine , capecitabine , regimen , cisplatin , chemotherapy , neoadjuvant therapy , surgery , survival rate , adenocarcinoma , oncology , gastroenterology , cancer , colorectal cancer , breast cancer
Adenocarcinoma of the esophagogastric junction (AEG) is refractory even when curative resection is followed by adjuvant chemotherapy. This study evaluated the efficacy of neoadjuvant chemotherapy (NAC) using an oral fluoropyrimidine-platinum regimen for AEG.